AAAAAA

   
Results: 1-25 | 26-32
Results: 1-25/32
Long-term evaluation of T-cell subset changes after effective combination antiretroviral therapy during asymptomatic HIV-infection
Authors: Bisset, LR Cone, RW Fischer, M Battegay, M Vernazza, PL Dubs, RW Weber, R Grob, PJ Opravil, M
Citation: Lr. Bisset et al., Long-term evaluation of T-cell subset changes after effective combination antiretroviral therapy during asymptomatic HIV-infection, J ACQ IMM D, 27(3), 2001, pp. 266-271
Quantification of in vivo replicative capacity of HIV-1 in different compartments of infected cells
Authors: Funk, GA Fischer, M Joos, B Opravil, M Gunthard, HF Ledergerber, B Bonhoeffer, S
Citation: Ga. Funk et al., Quantification of in vivo replicative capacity of HIV-1 in different compartments of infected cells, J ACQ IMM D, 26(5), 2001, pp. 397-404
Discontinuation of primary prophylaxis in HIV-infected patients at high risk of Pneumocystis carinii pneumonia: prospective multicentre study
Authors: Furrer, H Opravil, M Rossi, M Bernasconi, E Telenti, A Bucher, H Schiffer, V Boggian, K Rickenbach, M Flepp, M Egger, M
Citation: H. Furrer et al., Discontinuation of primary prophylaxis in HIV-infected patients at high risk of Pneumocystis carinii pneumonia: prospective multicentre study, AIDS, 15(4), 2001, pp. 501-507
Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting
Authors: Miller, V Vandamme, AM Loveday, C Staszewski, S Lundgren, J Youle, M Ait-Khaled, M Boucher, C Brun-Vezinet, F Dedes, N Giaquinto, C Hertogs, K Houyez, F Perrin, L Pillay, D Schmit, JC Schuurman, R Lange, J Banhegyi, D Biondi, G Broekhuizen, A Bush-Donovan, C Camacho, R Carlier, H Clavel, F Clotet, B Clumeck, N Colebunders, R De Clerq, K De Jaegher, JJ De Schrijver, G De Smet, K Hall, W Harrigan, R Hatzakis, A Hellmann, N Hoetelmans, R Holtzer, C Katlama, C Larder, D Loriaux, E McCreedy, B Mulcahy, F Opravil, M Phillips, A Ruiz, N Shulse, E Sonnerborg, A Soriano, V Steel, H Vella, S Williams, A
Citation: V. Miller et al., Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting, AIDS, 15(3), 2001, pp. 309-320
Antiretroviral treatment monitoring with an improved HIV-1 p24 antigen test: An inexpensive alternative to tests for viral RNA
Authors: Schupbach, J Boni, J Flepp, M Tomasik, Z Joller, H Opravil, M
Citation: J. Schupbach et al., Antiretroviral treatment monitoring with an improved HIV-1 p24 antigen test: An inexpensive alternative to tests for viral RNA, J MED VIROL, 65(2), 2001, pp. 225-232
Predictors of sexual risk behavior in HIV-infected persons
Authors: Eich-Hochli, D Niklowitz, M Eich, P Zellweger, U Opravil, M
Citation: D. Eich-hochli et al., Predictors of sexual risk behavior in HIV-infected persons, NERVENARZT, 72(3), 2001, pp. 216-223
The SPICE study: 48-week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues
Authors: Moyle, G Pozniak, A Opravil, M Clumeck, N DelFraissy, JF Johnson, M Pelgrom, J Reynes, J Vittecoq, D DeLora, P Salgo, M Duff, F
Citation: G. Moyle et al., The SPICE study: 48-week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues, J ACQ IMM D, 23(2), 2000, pp. 128-137
Effects of early antiretroviral treatment on HIV-1 RNA in blood and lymphoid tissue: A randomized trial of double versus triple therapy
Authors: Opravil, M Cone, RW Fischer, M Vernazza, PL Bassetti, S Lorenzi, P Bisset, LR Ott, P Huber, W Knuchel, MC Roos, M Luthy, R Weber, R
Citation: M. Opravil et al., Effects of early antiretroviral treatment on HIV-1 RNA in blood and lymphoid tissue: A randomized trial of double versus triple therapy, J ACQ IMM D, 23(1), 2000, pp. 17-25
Use of HIV-1 p24 as a sensitive, precise and inexpensive marker for infection, disease progression and treatment failure
Authors: Schupbach, J Tomasik, Z Nadal, D Ledergerber, B Flepp, M Opravil, M Boni, J
Citation: J. Schupbach et al., Use of HIV-1 p24 as a sensitive, precise and inexpensive marker for infection, disease progression and treatment failure, INT J ANT A, 16(4), 2000, pp. 441-445
Residual HIV-RNA levels persist for up to 2.5 years in peripheral blood mononuclear cells of patients on potent antiretroviral therapy
Authors: Fischer, M Gunthard, HF Opravil, M Joos, B Huber, W Bisset, LR Ott, P Boni, J Weber, R Cone, RW
Citation: M. Fischer et al., Residual HIV-RNA levels persist for up to 2.5 years in peripheral blood mononuclear cells of patients on potent antiretroviral therapy, AIDS RES H, 16(12), 2000, pp. 1135-1140
Transient rebound of plasma HIV-1 RNA is not followed by repopulation of the lymphoid compartment with HIV-1-infected cells
Authors: Joos, B Fischer, M Opravil, M Ott, P Weber, R Cone, RW
Citation: B. Joos et al., Transient rebound of plasma HIV-1 RNA is not followed by repopulation of the lymphoid compartment with HIV-1-infected cells, AIDS, 14(6), 2000, pp. 752-754
Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia
Authors: Yerly, S Kaiser, L Perneger, TV Cone, RW Opravil, M Chave, JP Furrer, H Hirschel, B Perrin, L
Citation: S. Yerly et al., Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia, AIDS, 14(3), 2000, pp. 243-249
Impact of TNF alpha, LT alpha, Fc gamma RII and complement receptor on HIV-1 trapping in lymphoid tissue from HIV-infected patients
Authors: Knuchel, MC Speck, RF Schlaepfer, E Kuster, H Ott, P Gunthard, HF Opravil, M Cone, RW Weber, R
Citation: Mc. Knuchel et al., Impact of TNF alpha, LT alpha, Fc gamma RII and complement receptor on HIV-1 trapping in lymphoid tissue from HIV-infected patients, AIDS, 14(17), 2000, pp. 2661-2669
Long-term hydroxyurea in combination with didanosine and stavudine for thetreatment of HIV-1 infection
Authors: Rutschmann, OT Vernazza, PL Bucher, HC Opravil, M Ledergerber, B Telenti, A Malinverni, R Bernasconi, E Fagard, C Leduc, D Perrin, L Hirschel, B
Citation: Ot. Rutschmann et al., Long-term hydroxyurea in combination with didanosine and stavudine for thetreatment of HIV-1 infection, AIDS, 14(14), 2000, pp. 2145-2151
Stopping primary prophylaxis in HIV-1-infected patients at high risk of toxoplasma encephalitis
Authors: Furrer, H Opravil, M Bernasconi, E Telenti, A Egger, M
Citation: H. Furrer et al., Stopping primary prophylaxis in HIV-1-infected patients at high risk of toxoplasma encephalitis, LANCET, 355(9222), 2000, pp. 2217-2218
Treatment-induced decline of human immunodeficiency virus-1 p24 and HIV-1 RNA in lymphoid tissue of patients with early human immunodeficiency virus-1 infection
Authors: Kuster, H Opravil, M Ott, P Schlaepfer, E Fischer, M Gunthard, HF Luthy, R Weber, R Cone, RW
Citation: H. Kuster et al., Treatment-induced decline of human immunodeficiency virus-1 p24 and HIV-1 RNA in lymphoid tissue of patients with early human immunodeficiency virus-1 infection, AM J PATH, 156(6), 2000, pp. 1973-1986
Clarithromycin, rifabutin and clofazimine for treatment of disseminated Mycobacterium avium complex disease in AIDS patients
Authors: Haefner, M Funke-Kissling, P Pfyffer, GE Luthy, R Opravil, M
Citation: M. Haefner et al., Clarithromycin, rifabutin and clofazimine for treatment of disseminated Mycobacterium avium complex disease in AIDS patients, CLIN DRUG I, 17(3), 1999, pp. 171-178
A randomized trial of interferon-alpha 2a and zidovudine versus bleomycin and zidovudine for AIDS-related Kaposi's sarcoma
Authors: Opravil, M Hirschel, B Bucher, HC Luthy, R
Citation: M. Opravil et al., A randomized trial of interferon-alpha 2a and zidovudine versus bleomycin and zidovudine for AIDS-related Kaposi's sarcoma, INT J STD A, 10(6), 1999, pp. 369-375
Bilateral cystoid macular edema following successful treatment of AIDS-associated CMV retinitis
Authors: Welzl-Hinterkorner, E Tholen, H Sturmer, J Opravil, M Bernauer, W
Citation: E. Welzl-hinterkorner et al., Bilateral cystoid macular edema following successful treatment of AIDS-associated CMV retinitis, OPHTHALMOLO, 96(2), 1999, pp. 87-91
Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort
Authors: Paris, D Ledergerber, B Weber, R Jost, J Flepp, M Opravil, M Ruef, C Zimmerli, S
Citation: D. Paris et al., Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort, AIDS RES H, 15(18), 1999, pp. 1631-1638
Cost-effectiveness of azithromycin for preventing Mycobacterium avium complex infection in HIV-positive patients in the era of highly active antiretroviral therapy
Authors: Sendi, PP Craig, BA Meier, G Pfluger, D Gafni, A Opravil, M Battegay, M Bucher, HC
Citation: Pp. Sendi et al., Cost-effectiveness of azithromycin for preventing Mycobacterium avium complex infection in HIV-positive patients in the era of highly active antiretroviral therapy, J ANTIMICRO, 44(6), 1999, pp. 811-817
The year in review: antiretroviral treatment
Authors: Hirschel, B Opravil, M
Citation: B. Hirschel et M. Opravil, The year in review: antiretroviral treatment, AIDS, 13, 1999, pp. S177-S187
Impact of drug resistance mutations on virologic response to salvage therapy
Authors: Lorenzi, P Opravil, M Hirschel, B Chave, JP Furrer, HJ Sax, H Perneger, TV Perrin, L Kaiser, L Yerly, S
Citation: P. Lorenzi et al., Impact of drug resistance mutations on virologic response to salvage therapy, AIDS, 13(2), 1999, pp. F17-F21
Quality of life in asymptomatic patients with early HIV infection initiating antiretroviral therapy
Authors: Zinkernagel, C Ledergerber, B Battegay, M Cone, RW Vernazza, P Hirschel, B Opravil, M
Citation: C. Zinkernagel et al., Quality of life in asymptomatic patients with early HIV infection initiating antiretroviral therapy, AIDS, 13(12), 1999, pp. 1587-1589
Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study
Authors: Ledergerber, B Egger, M Opravil, M Telenti, A Hirschel, B Battegay, M Vernazza, P Sudre, P Flepp, M Furrer, H Francioli, P Weber, R
Citation: B. Ledergerber et al., Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study, LANCET, 353(9156), 1999, pp. 863-868
Risultati: 1-25 | 26-32